These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 33367981)

  • 21. Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population.
    Visaria J; Uzoigwe C; Swift C; Dang-Tan T; Paprocki Y; Willey VJ
    Clin Ther; 2021 May; 43(5):808-821. PubMed ID: 33785221
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of the glucagon-like peptide-1 receptor agonist oral semaglutide in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
    Li J; He K; Ge J; Li C; Jing Z
    Diabetes Res Clin Pract; 2021 Feb; 172():108656. PubMed ID: 33434602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database.
    Liu L; Chen J; Wang L; Chen C; Chen L
    Front Endocrinol (Lausanne); 2022; 13():1043789. PubMed ID: 36568085
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dosing Patterns of Dulaglutide and Semaglutide in Patients with Type 2 Diabetes in the United Kingdom and Germany: A Retrospective Cohort Study.
    Barrett A; Debackere N; Ribeiro A; Keapoletswe K; Zingel R; Coles B
    Adv Ther; 2023 Aug; 40(8):3446-3464. PubMed ID: 37286889
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Orally Administered Semaglutide Versus GLP-1 RAs in Patients with Type 2 Diabetes Previously Receiving 1-2 Oral Antidiabetics: Systematic Review and Network Meta-Analysis.
    Nuhoho S; Gupta J; Hansen BB; Fletcher-Louis M; Dang-Tan T; Paine A
    Diabetes Ther; 2019 Dec; 10(6):2183-2199. PubMed ID: 31599391
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.
    Wen J; Nadora D; Bernstein E; How-Volkman C; Truong A; Akhtar M; Prakash NA; Puglisi J; Frezza E
    Cureus; 2024 Sep; 16(9):e69008. PubMed ID: 39385875
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
    Pratley RE; Aroda VR; Lingvay I; Lüdemann J; Andreassen C; Navarria A; Viljoen A;
    Lancet Diabetes Endocrinol; 2018 Apr; 6(4):275-286. PubMed ID: 29397376
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness in Real World of Once Weekly Semaglutide in People with Type 2 Diabetes: Glucagon-Like Peptide Receptor Agonist Naïve or Switchers from Other Glucagon-Like Peptide Receptor Agonists: Results from a Retrospective Observational Study in Umbria.
    Di Loreto C; Minarelli V; Nasini G; Norgiolini R; Del Sindaco P
    Diabetes Ther; 2022 Mar; 13(3):551-567. PubMed ID: 35230650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral Semaglutide Versus Empagliflozin, Sitagliptin and Liraglutide in the UK: Long-Term Cost-Effectiveness Analyses Based on the PIONEER Clinical Trial Programme.
    Bain SC; Hansen BB; Malkin SJP; Nuhoho S; Valentine WJ; Chubb B; Hunt B; Capehorn M
    Diabetes Ther; 2020 Jan; 11(1):259-277. PubMed ID: 31833042
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-world clinical effectiveness of once-weekly semaglutide in patients with type 2 diabetes: a systematic literature review.
    Ruan Z; Jiang Y; Shi H; Jia R; Ung COL; Hu H
    Expert Rev Clin Pharmacol; 2023 Feb; 16(2):161-176. PubMed ID: 36706368
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal.
    Malkin SJP; Carvalho D; Costa C; Conde V; Hunt B
    Diabetol Metab Syndr; 2022 Feb; 14(1):32. PubMed ID: 35164855
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia.
    Malkin SJP; Russel-Szymczyk M; Liidemann G; Volke V; Hunt B
    Diabetes Ther; 2019 Feb; 10(1):159-176. PubMed ID: 30535837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-World Retrospective Study into the Effects of Oral Semaglutide (As a Switchover or Add-On Therapy) in Type 2 Diabetes.
    Candido R; Gaiotti S; Giudici F; Toffoli B; De Luca F; Velardi V; Petrucco A; Gottardi C; Manca E; Buda I; Fabris B; Bernardi S
    J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Real-World Clinical Experience of Semaglutide in Secondary Care Diabetes: A Retrospective Observational Study.
    Williams DM; Ruslan AM; Khan R; Vijayasingam D; Iqbal F; Shaikh A; Lim J; Chudleigh R; Peter R; Udiawar M; Bain SC; Stephens JW; Min T
    Diabetes Ther; 2021 Mar; 12(3):801-811. PubMed ID: 33565043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the Effectiveness of Liraglutide vs Semaglutide in a Veteran Population.
    Rana KB; Britnell SR; Gilbertson ME; Ibrahim SL
    J Pharm Pract; 2023 Oct; 36(5):1095-1101. PubMed ID: 35414304
    [No Abstract]   [Full Text] [Related]  

  • 37. Weekly Semaglutide vs. Liraglutide Efficacy Profile: A Network Meta-Analysis.
    Alsugair HA; Alshugair IF; Alharbi TJ; Bin Rsheed AM; Tourkmani AM; Al-Madani W
    Healthcare (Basel); 2021 Aug; 9(9):. PubMed ID: 34574899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical review of the efficacy and safety of oral semaglutide in patients with type 2 diabetes considered for injectable GLP-1 receptor agonist therapy or currently on insulin therapy.
    Wright EE; Aroda VR
    Postgrad Med; 2020 Nov; 132(sup2):26-36. PubMed ID: 32815423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Once-Daily Oral Semaglutide Versus Injectable GLP-1 RAs in People with Type 2 Diabetes Inadequately Controlled on Basal Insulin: Systematic Review and Network Meta-analysis.
    Chubb B; Gupta P; Gupta J; Nuhoho S; Kallenbach K; Orme M
    Diabetes Ther; 2021 May; 12(5):1325-1339. PubMed ID: 33723769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Switch-to-Semaglutide Study (STS-Study): a Retrospective Cohort Study.
    Hepprich M; Zillig D; Florian-Reynoso MA; Donath MY; Rudofsky G
    Diabetes Ther; 2021 Mar; 12(3):943-954. PubMed ID: 33615400
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.